Detection of Human Antibody against the Human Papillomavirus Type 16 E7 Protein

Abstract

We examined 500 human sera for the presence of antibody against the human papillomavirus type 16 E7 protein by enzyme‐linked immunosorbent assay with bacterially expressed fusion protein lac‐E7, and by radioimmunoprecipitation and immunofluorescence assays with the E7 protein expressed in monkey COS‐1 cells. The anti‐E7 antibody was detectable in 6 out of 54 cases of cervical carcinoma, but in none of the others, including patients with other gynecologic cancers, those with sexually transmitted diseases, and healthy adults. The data indicate that expression of the E7 protein is closely related to cervical carcinoma.

Prevalence of Serum IgG Antibodies for the E7 and L2 Proteins of Human Papillomavirus Type 16 in Cervical Cancer Patients and Controls.

“…Our findings clearly demonstrated that the patient group exhibits a higher prevalence of the antibodies to the HPV16E7 product than the control, as shown by previous studies (Hashido et al 1991;Mandelson et al 1992;Sasagawa et al 1992). The L2 protein encodes a minor capsid protein (Yaegashi et al 1991) that induces a higher response of antibody than other HPV encoded proteins ), probably because the primary response may be induced by the L2 molecules of exogenous infected virions.…”

“…However, statistical analysis did not show any significant difference in the prevalence of the antibodies among histological groups. Some studies have revealed the relationship between the clinical stage of uterine cervical cancer and HPV infection (Hashido et al 1991;Sasagawa et al 1992), that is, progression of the stage is related to a higher incidence of HPV antibody. In our study, E7 and L2 antibodies were positive in 16% (8/49) and 33% (16/49) of early stage (stage I and II) patients, and 25% (2/8) and 25% (2/ 8) of late stage (stage III and IV) patients, respectively.…”

Occurrence of the Antibody against Human Papillomavirus Type 16 Virion Protein L2 in Patients with Cervical Cancer and Dysplasia

“…Cooperation of these viral oncoproteins induces immortalization of human primary keratinocytes in vitro [8,9]. Cervical carcinoma cells selectively retain the E6 and E7 genes intact [10], and their growth in vitro depends on the expression of these genes [11,12], Furthermore, the antibodies against E6 and E7 proteins are associated with cervical cancer [13][14][15][16][17][18][19], Thus, HPV 16 E6 and E7 proteins appeared to play a major role in carcinogenesis.…”

Asociación entre la presencia de anticuerpos anti-Ras y anti-VPH16 E4/E7 y lesiones intraepiteliales del cérvix

“…de mujeres positivas para anticuerpos * La RM para las mujeres que fueron negativas para anticuerpos, no predicen algún riesgo y resultaron no tener significancia estadística ‡ NP = Lesión no neoplásica fueron hasta en 87% positivas para anticuerpos anti-E7. La asociación de anticuerpos contra proteínas oncogénicas VPH con CaCu ha sido ampliamente investigada, 9,10,[31][32][33] sin embargo, nuestros resultados mostraron una alta asociación entre la presencia de anticuerpos anti-E7 y lesiones del tipo NIC III, riesgo que se incrementa hasta en 17.8 veces, si se consideran todos los casos positivos para secuencias del VPH. Esto demuestra que la presencia de anticuerpos anti-E7 está asociada de manera importante con el desarrollo de lesiones NIC III, dato que no había sido reportado en otros estudios y que pudiera ser de utilidad como marcador para este tipo de lesión.…”